GPAS 2025: Shaping the Future of Bleeding Disorder Care
The World Federation of Hemophilia (WFH) recently shared an insightful post on X:
”At GPAS 2025, global experts explored the evolving treatment landscape for bleeding disorders—highlighting innovations in hemophilia and VWD care, and addressing challenges in access and reimbursement. A timely look at what’s ahead in care.”
At GPAS 2025, leading global experts Jamie O’Hara, Alok Srivastava, Nathan Connell and Cedric Hermans convened to discuss the rapidly evolving treatment landscape for bleeding disorders.
Sessions spotlighted innovation in hemophilia and von Willebrand disease (VWD) care, including novel therapeutics, personalized medicine, and gene-based approaches.
Critical dialogue also addressed ongoing challenges in access, affordability, and reimbursement.
The meeting offered a timely and forward-looking perspective on the future of equitable care delivery!
Find more footage from the webinar in the gallery.
Hemostasis Today, your daily update on the World of Hemophilia.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis